Rociletinib (CO1686) |
|
| Synonyms: N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO1686; AVL-301; CNX-419 ;AVL 301; AVL301; CNX419 | |
| Cat. No.: R60000 | CAS No.: 1374640-70-6 |
| MDL.: | Formula: C27H28F3N7O3 |
| F.W.555.25 | Purity: 99% |
| Storage: | |
| Size/Unit | Price | Qty | Availability | Price Total |
|---|---|---|---|---|
| 5mg | $150.00 | Enter qty and click checkbox |
 
|
$150.00 |
| Catalog Number： | R60000 | CAS No.: | 1374640-70-6 | |
| MDL: | Formula: | C27H28F3N7O3 | ||
| F.W.: | 555.25 | Purity: | 99% | |
| Package: | Unit: | mg | ||
| Appearance: | M.P.: | |||
| B.P.: | Density: | |||
| Optical Rotation: | Refractive Index: | |||
| Solubility: | DMSO | Stability: | ||
| Storage: | Category: | Reference Standard | ||
| Application: | CO-1686 is a novel, oral, targeted covalent (irreversible) inhibitor of the cancer-causing mutant forms of epidermal growth factor receptor (EGFR) currently being studied for the treatment of non-small cell lung cancer (NSCLC). | |||